4-[(Butylcarbamoyl)amino]benzoic acid | 51739-79-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(Butylcarbamoyl)amino]benzoic acid
• 英文别名: 4-(butylcarbamoylamino)benzoic acid
• CAS: 51739-79-8
• 化学式: C₁₂H₁₆N₂O₃
• mdl: MFCD03229105
• 分子量: 236.27
• InChiKey: HXHWWLZVCKDTIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  申请人：Beavers Lisa Selsam

  公开号：US20100160319A1

  公开（公告）日：2010-06-24

  The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I)

  本发明披露了公式I的新化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或反向激动剂活性，以及制备这种化合物的方法。在另一个实施例中，本发明披露了包含公式I化合物的药物组合物，以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。（公式I）
• Histamine H3 receptor agents, preparation and therapeutic uses
  申请人：Eli Lilly and Company

  公开号：EP2322506A1

  公开（公告）日：2011-05-18

  The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

  本发明公开了具有组胺-H3受体拮抗剂或反向激动剂活性的新型式I化合物或其药学上可接受的盐，以及制备此类化合物的方法。在另一个实施方案中，本发明公开了包含式 I 化合物的药物组合物以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺 H3 受体相关疾病的方法。
• US8008296B2
  申请人：——

  公开号：US8008296B2

  公开（公告）日：2011-08-30
• [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] AGENTS RECEPTEURS DE L'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2007005503A1

  公开（公告）日：2007-01-11

  [EN] The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I)
  [FR] L'invention se rapporte à de nouveaux composés de la formule 1 ou à des sels pharmaceutiquement acceptables de ces derniers qui possèdent une activité antagoniste ou agoniste inverse du récepteur à l'histamine H3, et à des procédés de préparation desdits composés. Dans un autre mode de réalisation, l'invention concerne des compositions pharmaceutiques comprenant des composés de la formule 1, et des procédés d'utilisation de ces derniers pour traiter l'obésité, les déficiences cognitives, la narcolepsie et d'autres affections liées au récepteur de l'histamine H3.